An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.
An international research team has developed a new strategy that can predict the potential clinical implications of new therapeutic compounds based on simple cellular responses. This discovery was partly led by scientists affiliated with Université de Montréal (UdeM), and represents a major step forward in developing more effective drugs with fewer side effects, much faster than before. The researchers conducted their work at Centre de Recherche de l’Hôpital Ste-Justine and published their findings in the prestigious journal Nature Communications.
Developing new drugs is a long, complex and costly process. It starts with identifying the molecule or “ligand” (such as a drug, hormone or neurotransmitter) that can activate or block the target or “receptor” involved in a disease. Compound identification and validation is one of the most important steps in ensuring that a new drug provides an effective clinical response with the fewest possible side effects.
“Most new drugs tested on human subjects fail in clinical trials because the therapeutic response is insufficient. Developing a strategy that infers potential clinical responses early in the drug discovery process would significantly improve drug candidate selection,” said Besma Benredjem, the study’s co-lead author and a doctoral student in pharmacology at UdeM.
Finding the needle in a haystack
“Our main goal was finding a way to categorize a large number of drug candidates based on similarities in their effectiveness in triggering a multiplicity of cellular responses that help identify the therapeutic action of new compounds,” said Professor Graciela Piñeyro, co-senior author of the study and a researcher at CHU Sainte-Justine. To accomplish this, she worked with Dr. Olivier Lichtarge of Baylor College of Medicine, who uses advanced bioinformatic analysis to compare and group ligands according to fairly comprehensive signalling profiles.
Drugs produce desired or undesired clinical actions by changing basic signals within cells. By grouping drugs with known clinical actions and new ligands, we can infer the clinical actions of new compounds by comparing the similarities and differences in their signals with known drugs to promote desired clinical responses and avoid side effects.
This method of analysis was developed by using opioid analgesics as prototypes. This made it possible for the team to associate simple cellular signals produced by opioids such as oxycodone, morphine and fentanyl with the frequency with which respiratory depression and other undesirable side effects of these drugs were reported to the Food and Drug Administration’s pharmacovigilance program. At the height of the opioid epidemic, when the risk of death by respiratory depression is at its highest, the team believes this new analytical strategy could lead to the development of safer opioids.
“Thanks to our findings, we can now classify a large number of compounds while taking a multitude of cellular signals into account. The wealth of comparisons this provides increases this classification’s predictive value for clinical responses,” said Professor Michel Bouvier, the study’s co-senior author and a principal investigator of molecular pharmacology and Chief Executive Officer of UdeM’s Institute for Research in Immunology and Cancer. “We think we can help patients by speeding up the drug discovery process so clinical trials can start earlier.”
“Our next goal is to use a similar approach to test cannabis products that may produce harmful neuropsychiatric actions among young people, and identify which cannabis extracts are most effective at treating chronic pain,” added Besma Benredjem.
Learn more: Speeding up the drug discovery process to help patients
The Latest on: Drug development
[google_news title=”” keyword=”drug development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Drug development
- Psychedelicnewsbreaks Psychedelic Therapeutics And Drug Development Conference Partners With Psychedelicnewswire As Official Media Sponsoron May 17, 2024 at 8:52 pm
The Psychedelic Therapeutics and Drug Development announced that PsychedelicNewsWire (“PNW), a specialized communications platform for the psychedel ...
- Parallel Bio launches Clinical Trial in a Dish to predict drug efficacyon May 17, 2024 at 6:39 am
US-based biotech company Parallel Bio has introduced 'Clinical Trial in a Dish' to enhance early-stage drug discovery. This innovative approach utilises human immune organoids and robotics to simulate ...
- BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorderson May 16, 2024 at 6:59 am
BullFrog AI and LIBD have made remarkable progress in identifying novel subgroups between and within neuropsychiatric disorders, including major depression, schizophrenia, and bipolar disorder.
- 4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MAon May 16, 2024 at 6:57 am
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- via PsychedelicNewsWire (“PNW”) — Following three impactful conferences, Arrowhead Sci-Tech ...
- Biogen, Ionis to discontinue development of experimental ALS drugon May 16, 2024 at 4:40 am
Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their treatment for amyotrophic lateral sclerosis (ALS) based on results from an early-stage study.
- Heating proteins to body temperature reveals new drug targetson May 15, 2024 at 4:05 pm
Some proteins shift their shape when exposed to different temperatures, revealing previously unknown binding sites for medications. The findings could revolutionize wide swathes of biology by ...
- Chinese biotech crackdown would reset U.S. drug developmenton May 15, 2024 at 2:30 am
Lawmakers in the House of Representatives on Wednesday are expected to set in motion a massive reordering of how U.S. pharmaceuticals are developed and made, by advancing a contracting ban on five key ...
- More than 20,000 volunteers join effort to accelerate dementia drug developmenton May 14, 2024 at 11:57 pm
More than 20,000 volunteers have been recruited to a resource aimed at speeding up the development of much-needed dementia drugs. The cohort will enable scientists in universities and industry to ...
- Roquette solving toughest drug development challenges with new capsuleson May 14, 2024 at 3:41 am
Roquette, a global leader in plant-based ingredients and a key provider of pharmaceutical and nutraceutical excipients, announced today (May 14) the launch of its innovative Lycagel Flex hydroxypropyl ...
- Life science leaders on how to make drug development less expensive, slow, and riskyon May 7, 2024 at 1:02 pm
New ways of identifying and testing therapies, a more precise understanding of disease, and a renewed sense of urgency could help speed up drug development.
via Bing News